Ascendis Pharma A/S

ASND

US04351P1012

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-09-20 pm EDT			5-day change	1st Jan Change
151.26 ^USD	-1.41%		+26.87%	+20.10%

Sep. 20	Sector Update: Health Care Stocks Rise Premarket Friday	MT
Sep. 20	Ascendis Pharma Prices Offering of American Depositary Shares	MT

This article is reserved for members

To unlock the article, REGISTER!

100% Free Registration

Vous êtes déja client ? Log In

Latest news about Ascendis Pharma A/S

Sector Update: Health Care Stocks Rise Premarket Friday	Sep. 20	MT
Ascendis Pharma Prices Offering of American Depositary Shares	Sep. 20	MT
European Equities Traded in the US as American Depositary Receipts Rise Sharply in Thursday Trading	Sep. 19	MT
Ascendis Pharma Unveils $300 Million ADS Offering	Sep. 18	MT
European Equities Traded in the US as American Depositary Receipts Edge Lower in Tuesday Trading	Sep. 17	MT
Oppenheimer Raises Ascendis Pharma A/S Price Target to $190 From $180, Maintains Outperform Rating	Sep. 17	MT
Evercore Raises Price Target on Ascendis Pharma to $205 From $191, Keeps Outperform Rating	Sep. 17	MT
European Equities Traded in the US as American Depositary Receipts Higher in Monday Trading	Sep. 16	MT
Ascendis Pharma Says Trial of Potential Dwarfism Drug Achieved Primary Endpoint	Sep. 16	MT
Ascendis Pharma A/S - Special Call	Sep. 16
Ascendis Pharma A/S Announces Pivotal ApproaCH Trial of TransCon CNP (Navepegritide) Achieved Primary Objective, Demonstrated AGV Superior to Placebo	Sep. 16	CI
European Equities Close Higher on Friday; HSBC Mulls Potential Sale of South African Unit	Sep. 13	MT
Ascendis Says Initial Data Shows Anti-Tumor Activity in Phase 1/2 Platinum-Resistant Ovarian Cancer Trial	Sep. 13	MT
Ascendis to Present First Results from Platinum-Resistant Ovarian Cancer Cohort of the Phase 1/2 Il-Believe Trial At Esmo 2024	Sep. 13	CI
Ascendis Pharma Gets FDA Orphan Drug Designation for Hypoparathyroidism Treatment	Sep. 12	MT
Ascendis Pharma Gets Orphan Drug Exclusivity for Hormone Treatment Yorvipath in U.S.	Sep. 11	DJ
Oppenheimer Upgrades Ascendis Pharma A/S to Outperform From Perform, $180 Price Target	Sep. 05	MT
European Equities Traded in the US as American Depositary Receipts Flat in Wednesday Trading	Sep. 04	MT
Sector Update: Health Care Stocks Fall Premarket Wednesday	Sep. 04	MT
Royalty Pharma, Ascendis Pharma Unit Have $150 Million Royalty Funding Agreement	Sep. 03	MT
Ascendis Pharma Q2 Loss Narrows, Sales Slump -- Shares Plunge After Hours	Sep. 03	MT
Earnings Flash (ASND) ASCENDIS PHARMA Reports Q2 Revenue EUR36M	Sep. 03	MT
Ascendis Pharma A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	Sep. 03	CI
Ascendis Pharma A/S, Q2 2024 Earnings Call, Sep 03, 2024	Sep. 03
Evercore ISI Raises Price Target on Ascendis Pharma to $200 From $191, Keeps Outperform Rating	Aug. 26	MT

Ascendis Pharma A/S is a Denmark-based company that manufactures pharmaceutical products. The Company produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The Company operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).

Employees

879

Sector

Biotechnology & Medical Research

Calendar

2024-11-05 - Q3 2024 Earnings Release (Projected)

More about the company